Baxter International Inc. (BAX) — 分析摘要
Baxter International Inc.（BAX）的市值为11.26十亿美元，最近一年的营收同比增长了+5.7%。净利润率为-8.5%。当前市盈率为-10.3倍。
核心要点
- 营收同比变化+5.7%
- 净利润率-8.5%
- 市盈率-10.3倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，BAX的营收增长为+5.7%，市盈率为-10.3倍。
Baxter International Inc. (BAX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -1.4x — 盈利不足以覆盖利息支出
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
37,500
总部
DEERFIELD, IL
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.04
股息收益率
0.18%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。